CNTA News and Press, Centessa Pharmaceuticals plc

2024-06-21 11:15:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for CNTA on June 21, 2024 09:17AM ET. The previous analyst recommendation was Equal-Weight. CNTA was trading at $9.28 at issue of the analyst recommendation. The overall analyst consensus : ...

2024-06-10 11:11:48 ET More on Centessa Pharmaceuticals Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point Centessa Pharmaceuticals prices $100M ADS offering Read the full article on Seeking Alpha For further details see: Centessa Pharmace...

BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Fi...

Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024 Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and sel...

Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...

2024-04-30 06:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-24 14:20:33 ET Summary Centessa Pharmaceuticals plc interim data from the PRESent-2 study, using SerpinPC for the treatment of patients with Hemophilia B without inhibitors, is expected to be released in 2024. PRESent-3 is another registrational study using SerpinPC for th...

2024-04-24 03:11:08 ET More on Centessa Pharmaceuticals Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential Seeking Alpha’s Quant Rating on Centessa Pharmaceuticals Historical earnings data for Centessa Pharmaceutic...

BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public of...

2024-04-23 16:33:58 ET More on Centessa Pharmaceuticals Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential Seeking Alpha’s Quant Rating on Centessa Pharmaceuticals Historical earnings data for Centessa Pharmaceutic...